Iterum Therapeutics Expands ORLYNVAH Market Access While FDA Requires Additional Clinical Trial for Step-Down Therapy
核心洞察
Iterum Therapeutics (搜索) secured a rebate agreement with a top Medicare Part D Pharmacy Benefit Manager, expanding ORLYNVAH coverage to over 3.5 million additional lives starting this quarter.
The company received a new U.S. patent covering ORLYNVAH's bilayer tablet formulation that extends protection until December 2039 and qualifies for Orange Book listing.
FDA determined that Iterum must conduct an adequate clinical trial through a supplemental new drug application to support ORLYNVAH as step-down therapy for complicated urinary tract infections (搜索).
Iterum Therapeutics (搜索) plc announced significant developments in market access and regulatory positioning for ORLYNVAH™ (oral sulopenem), while facing additional clinical trial requirements for expanded therapeutic indications. The Dublin and Chicago-based company, which focuses on delivering next-generation oral and IV antibiotics to treat multi-drug resistant pathogen infections (搜索), provided the business update on February 13, 2026.
Medicare Coverage Expansion Reaches Millions
The company achieved a major market access milestone by securing another signed rebate agreement with one of the top three Medicare Part D Pharmacy Benefit Managers. This agreement complements existing agreements with the other two top Medicare Part D managers, positioning ORLYNVAH for inclusion on Medicare Advantage Prescription Drug and Medicare Prescription Drug formularies. The expanded coverage is expected to reach more than 3.5 million lives beginning as early as this quarter.
Patent Protection Extended Through 2039
Iterum strengthened its intellectual property portfolio with the grant of U.S. patent number 12,544,337, entitled "Combinations of Beta-Lactam Compounds and Probenecid and Uses Thereof." The patent covers a bilayer tablet comprising sulopenem etzadroxil and probenecid, manufacturing methods for the bilayer tablet, and treatment methods for diseases including uncomplicated urinary tract infection. The patent is projected to expire in December 2039, absent any patent term extensions, assuming timely payment of all maintenance fees. This Orange Book listable patent would bring Iterum's total to five U.S. patents listed in the FDA's Orange Book.
FDA Sets Clinical Trial Requirements for Expanded Use
The U.S. Food and Drug Administration responded to Iterum's request regarding ORLYNVAH as step-down therapy and real-world data collection to support the proposed claim. The FDA determined that Iterum must provide substantial evidence of effectiveness from an adequate and well-designed clinical trial in a supplemental new drug application (sNDA) to support the proposed indication for ORLYNVAH as step-down treatment of complicated urinary tract infections (搜索) (cUTI). The agency recommended that Iterum request a Type C meeting to discuss the design and endpoints of any proposed clinical investigation supporting the proposed indication.
Current Therapeutic Profile
ORLYNVAH is a novel oral penem antibiotic approved for treating uncomplicated urinary tract infections (搜索) caused by designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis (搜索) in adult women with limited or no alternative oral antibacterial treatment options. The drug possesses potent activity against species of Enterobacterales (搜索), including those that encode ESBL or AmpC-type β-lactamases that confer resistance to third-generation cephalosporins.
Iterum's lead compound sulopenem, available in both oral and IV formulations, has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. The company has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for both oral and IV formulations of sulopenem across seven indications.